• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amgen (NQ: AMGN )

    316.91 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amgen

    < Previous 1 2
    ...
    11 12 13 14 15 16 17 18 19
    ...
    46 47 Next >
    $100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Johnson & Johnson Stock: Is Now the Time to Sell?
    Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff 
    Via InvestorPlace
    In-Depth Analysis: Amgen Versus Competitors In Biotechnology Industry
    Via Benzinga
    Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?
    The biotech is ending the year with a bang. 
    Via The Motley Fool
    Is Amgen Stock a Buy Now?
    The company recently closed its acquisition of Horizon Therapeutics. 
    Via The Motley Fool
    Check Out What Whales Are Doing With AMGN
    Via Benzinga
    Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks
    During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves. 
    Via MarketBeat
    Topics ETFs
    Expert Ratings for Amgen
    Via Benzinga
    $100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
    Via Benzinga
    Check Out What Whales Are Doing With AMGN
    Via Benzinga
    Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
    The company has growing pipeline optionality, according to the upgrade report. 
    Via Investor's Business Daily
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Should You Still Buy the Nasdaq's Best-Performing September Stocks?
    Tech stocks sold off last month, but these three were gainers. 
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
    These two healthcare stocks are reliable passive income vehicles. 
    Via The Motley Fool
    Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
    Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
    Via Investor's Business Daily
    Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
    According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX). 
    Via Benzinga
    FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer
    FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an... 
    Via Benzinga
    Exposures Product Safety
    Biotech Sector: On The Verge Of Triumph Or Turmoil?
    In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
    Via Talk Markets
    Should You Still Buy the Dow Jones' Best-Performing September Stocks?
    A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy. 
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns
    The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ: 
    Via Benzinga
    Exposures Product Safety
    Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
    All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
    Via Benzinga
    AskSlim Market Week - Friday, Sep. 29
    Technical and cycle analysis, and market commentary. 
    Via Talk Markets
    3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
    The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States. 
    Via InvestorPlace
    September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
    The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
    The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of... 
    Via Benzinga
    Exposures Product Safety
    Argenx's 28% Surge & Promising Product Propel Investor Confidence
    Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
    Via MarketBeat
    AI To Revolutionize Clinical Trials And Diagnostics
    With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
    FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
    Via FinancialNewsMedia
    From Years to Months: How AI is Shaping the Landscape of Clinical Trials
    Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    < Previous 1 2
    ...
    11 12 13 14 15 16 17 18 19
    ...
    46 47 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.